Crohns Disease Treatment Market Size & Share Report, 2032

Crohns Disease Treatment Market – By Treatment (Medication {Anti-inflammatory Agents, Immunosuppressants, Antibiotics, Antipyretics}, Nutritional Therapy, Surgery), Dosage Form (Oral, Parenteral), Age Group, End-use, Global Forecast 2024 ­ 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of crohn&rsquo;s disease

3.2.1.2&nbsp;&nbsp;&nbsp; Advancement in diagnostic techniques

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing research &amp; development activities for drug development

3.2.1.4&nbsp;&nbsp;&nbsp; Increased awareness about crohn&#39;s disease

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Complexity of disease management

3.2.2.2&nbsp;&nbsp;&nbsp; Lack of curative treatments

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Pipeline analysis

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategic dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Medication

5.2.1&nbsp;&nbsp;&nbsp; Anti-inflammatory agents

5.2.2&nbsp;&nbsp;&nbsp; Immunosuppressants

5.2.3&nbsp;&nbsp;&nbsp; Antibiotics and antipyretics

5.2.4&nbsp;&nbsp;&nbsp; Other medications

5.3&nbsp;&nbsp;&nbsp; Nutritional therapy

5.4&nbsp;&nbsp;&nbsp; Surgery

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Oral

6.3&nbsp;&nbsp;&nbsp; Parenteral

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Pediatric

7.3&nbsp;&nbsp;&nbsp; Adult

7.4&nbsp;&nbsp;&nbsp; Geriatric

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals &amp; clinics

8.3&nbsp;&nbsp;&nbsp; Homecare settings

8.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Netherlands

9.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

9.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; AbbVie Inc.

10.2&nbsp;&nbsp;&nbsp; Amgen Inc.

10.3&nbsp;&nbsp;&nbsp; AstraZeneca Plc

10.4&nbsp;&nbsp;&nbsp; Biogen

10.5&nbsp;&nbsp;&nbsp; Boehringer Ingelheim GmbH

10.6&nbsp;&nbsp;&nbsp; Bristol Myerr Squibb

10.7&nbsp;&nbsp;&nbsp; Eli Lilly and Company

10.8&nbsp;&nbsp;&nbsp; Janssen Pharmaceuticals (Johnson &amp; Johnson)

10.9&nbsp;&nbsp;&nbsp; Merck &amp; Co. Inc

10.10&nbsp;&nbsp;&nbsp;Novartis AG

10.11&nbsp;&nbsp;&nbsp;Pfizer, Inc.

10.12&nbsp;&nbsp;&nbsp;Salix Pharmaceuticals, Inc.

10.13&nbsp;&nbsp;&nbsp;Takeda Pharmaceutical Industries Limited

10.14&nbsp;&nbsp;&nbsp;Viatris Inc. (Mylan N.V.) 
&nbsp;

Crohns Disease Treatment Market

Get a free sample of this report